Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Arrayjet plays a key role in the development of anti-malarial vaccination

The quest to develop effective malarial vaccines is now a step closer with Scottish bio-printer manufacturer Arrayjet, selected to work with a Kenyan-based medical research group to assist ongoing R&D trials that could lead to a vaccination immunization program to tackle malaria in less than two years.

17 Mar 2021

Compromised immunity can allow SARS-CoV-2 to evade the immune system

The vast majority of people infected with SARS-CoV-2 clear the virus, but those with compromised immunity--such as individuals receiving immune-suppressive drugs for autoimmune diseases--can become chronically infected.

17 Mar 2021

Living with a COVID-19 case brings worse symptoms and stronger antibody response

This study suggests that high virus exposure levels contribute to greater disease severity and stronger antibody responses. The observations from this study are published on the medRxiv preprint server.

17 Mar 2021

Salivary IgG to SARS-CoV-2 after mild COVID-19

A team of researchers based in Stockholm, Sweden, has demonstrated that individuals exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have antibodies for the disease up to nine months after acquiring the disease, even if they displayed only mild symptoms.

16 Mar 2021

New Colombian SARS-CoV-2 lineage shares antibody-resistant mutations with other variants

Scientists in Colombia have identified a new highly divergent SARS-CoV-2 lineage with Spike substitutions L249S and E484K. These same mutations have convergently appeared in other mutant strains of the virus, most notably in variants of concern.

16 Mar 2021

Saliva-based testing as a method for monitoring population immunity to SARS-CoV-2 infection

Researchers in the United States have shown that saliva-based sampling could serve as an accurate and non-invasive alternative to blood sampling for monitoring people’s antibody responses following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or vaccination against the virus.

16 Mar 2021

UTHSC professor awarded $1.79 million grant to develop new amyloidosis treatment

The National Institute of Diabetes and Digestive and Kidney Diseases recently awarded Jonathan Wall, PhD, professor in the University of Tennessee Health Science Center's Graduate School of Medicine in Knoxville, a $1.79 million grant for his study titled "Developing a Theranostic Immunotherapy for Systemic Amyloidosis."

16 Mar 2021

SARS-CoV-2 Brazilian variant may potentially escape T cell-mediated host immune responses

A team of scientists from Brazil recently explored the abilities of the UK, South African, and Brazilian variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to evade host CD8+ T cell responses induced by natural infection or vaccination. The findings reveal reduced antigenic coverage for the P.2 Brazilian lineage, indicating its ability to evade SARS-CoV-2-induced T cell responses.

16 Mar 2021

Ferret study shows SARS-CoV-2 airborne transmission dynamics

A team of researchers led by Sander Herfst from Erasmus University Medical Center in The Netherlands suggests severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could spread through the air at a one-meter distance and cause infection in a new ferret model study.

16 Mar 2021

Study explores how SARS-CoV-2 mutations produce antibody resistance and enhanced transmissibility

An interesting new study deals with the effects of the natural mutations in the spike antigen of the SARS-CoV-2, the pathogen that is responsible for the ongoing coronavirus disease pandemic.

16 Mar 2021

New study tests how mutations in SARS-CoV-2 affect antibody neutralization

Using pseudoviruses with single amino acid substitutions, researchers found that mutations in SARS-CoV-2 reduce monoclonal antibody neutralization differently. However, convalescent sera samples did not lose neutralization potency many and were also effective against the B.1.1.7 (UK-derived) strain.

16 Mar 2021

Chimeric vaccines may provide universal protection against viruses like SARS-CoV-2

Researchers in the United States have developed “chimeric” vaccines that provided cross-protection against different strains of sarbecovirus in mice, including the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19).

15 Mar 2021

Scientists discover how novel pathogens promote colorectal cancer development

Do BMMFs, the novel infectious agents found in dairy products and bovine sera, play a role in the development of colorectal cancer? Scientists led by Harald zur Hausen detected the pathogens in colorectal cancer patients in close proximity to tumors.

15 Mar 2021

What is a protective neutralizing antibody titer against SARS-CoV-2 infection?

A new study describes a predictive model of protective immunity against SARS-CoV-2 infection that could help evolve optimal vaccination strategies to maintain protection and reduce the death rate.

15 Mar 2021

Why does convalescent plasma therapy for severe COVID-19 show mixed success?

A surprising new preprint, released on the medRxiv* server, suggests that the beneficial effects of convalescent plasma (CP) in this disease stem not only from the presence of neutralizing antibodies, but also the immunomodulatory effects of this plasma that shapes the host immune response.

15 Mar 2021

Neutralizing nanobodies effective against SARS-CoV-2 variants

Nanobodies have different mechanisms to neutralize viruses, and some target epitopes not accessible to monoclonal antibodies, making them an alternative for developing therapies for COVID-19.

15 Mar 2021

Dual-action monoclonal antibodies from an original SARS survivor show promise against COVID-19

A recent study, currently available on the bioRxiv preprint server, indicates that a pair of dual-action monoclonal antibodies derived from an original 2003 SARS survivors could play an important role in the fight against coronavirus disease 2019 (COVID-19) due to their broadly neutralizing activity and the engagement of the immune system via effector function capabilities.

14 Mar 2021

Study maps crucial component of long-term immune response to SARS-CoV-2

Researchers in the United States have found that protective antibodies generated against the original strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)– the agent that causes coronavirus disease 2019 (COVID-19) – also protect against viral variants.

14 Mar 2021

Immuno-PET detects changes in different cancer receptors in response to targeted therapies

Immuno-positron emission tomography (PET) imaging can provide early insight into a tumor's response to targeted therapy, allowing physicians to select the most effective treatment for patients who have cancer.

13 Mar 2021

Neutralizing antibodies induced by COVID-19 vaccines less effective against new variants

SARS-CoV-2, the virus that causes COVID-19, has mutated throughout the pandemic. New variants of the virus have arisen throughout the world, including variants that might possess increased ability to spread or evade the immune system.

13 Mar 2021

Antibody News and Research

Further Reading

Arrayjet plays a key role in the development of anti-malarial vaccination

Compromised immunity can allow SARS-CoV-2 to evade the immune system

Living with a COVID-19 case brings worse symptoms and stronger antibody response

Salivary IgG to SARS-CoV-2 after mild COVID-19

New Colombian SARS-CoV-2 lineage shares antibody-resistant mutations with other variants

Saliva-based testing as a method for monitoring population immunity to SARS-CoV-2 infection

UTHSC professor awarded $1.79 million grant to develop new amyloidosis treatment

SARS-CoV-2 Brazilian variant may potentially escape T cell-mediated host immune responses

Ferret study shows SARS-CoV-2 airborne transmission dynamics

Study explores how SARS-CoV-2 mutations produce antibody resistance and enhanced transmissibility

New study tests how mutations in SARS-CoV-2 affect antibody neutralization

Chimeric vaccines may provide universal protection against viruses like SARS-CoV-2

Scientists discover how novel pathogens promote colorectal cancer development

What is a protective neutralizing antibody titer against SARS-CoV-2 infection?

Why does convalescent plasma therapy for severe COVID-19 show mixed success?

Neutralizing nanobodies effective against SARS-CoV-2 variants

Dual-action monoclonal antibodies from an original SARS survivor show promise against COVID-19

Study maps crucial component of long-term immune response to SARS-CoV-2

Immuno-PET detects changes in different cancer receptors in response to targeted therapies

Neutralizing antibodies induced by COVID-19 vaccines less effective against new variants

Using single B cell screening to boost antibody discovery eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo